Multitarget-Directed Multiple Ligands in Anti-VEGF Resistant Glioblastoma Therapeutics: An in Silico Approach to Identify Potential Phytochemicals

Abstract

Angiogenesis is an important process in tumor progression. Vascular endothelial growth factor (VEGF) is the key factor regulating angiogenesis, and hence, anti-VEGF therapy is considered a useful therapeutic approach in tumor conditions. However, the drug resistance and lack of efficacy of existing drugs limit the potential of such a therapeutic approach in certain cases, and the tumor growth will continue through alternative mechanisms. Glioblastoma (GBM) is one such type of tumor that shows resistance to anti-VEGF therapy. Previously, we identified the hub genes differentially expressed in anti-VEGF resistance in GBM. Medhya Rasayana, an Ayurvedic formulation, is used for the management of neurological disorders. In the present study, we used computational docking methods to identify the phytochemicals present in the medicinal plants of Medhya Rasayana, which can target the proteins expressed by the hub genes associated with anti-VEGF resistance. Network pharmacological analysis was also performed to identify the highly effective phytochemicals for a possible adjuvant therapy. Results showed that multiple phytochemicals of Glycirrhiza glabra Linn, Evolvulus alsinoides, and Celastrus paniculatus target the anti-VGEF resistant proteins in GBM. This indicates the multi-targeting property of phytocompounds of Medhya Rasayana plants, which may be considered for adjuvant therapy along with anti-VEGF therapy.

Keywords

glioblastoma / transcriptome data analysis / angiogenesis / anti-VEGF therapy / drug resistance / molecular docking / Medhya Rasayana

References

[1] Soumya, S. J., Arya, K. R., Abhinand, C. S., Sunitha, P., Athira, A. P., Nair, A. S., ..., & Sudhakaran, P. R. (2024). Multi—target and natural product—based multi—drug approach for anti—VEGF resistance in glioblastoma. Exploration of Drug Science, 2(5), 567-582. https://doi.org/10.37349/eds.2024.00062

[2] Soda, Y., Myskiw, C., Rommel, A., & Verma, I. M. (2013). Mechanisms of neovascularization and resistance to anti—angiogenic therapies in glioblastoma multiforme. Journal of Molecular Medicine, 91, 439-448. https://doi.org/10.1007/s00109-013-1019-z

[3] Piao, Y., Liang, J., Holmes, L., Henry, V., Sulman, E., & de Groot, J. F. (2013). Acquired resistance to anti—VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clinical Cancer Research, 19(16), 4392-4403. https://doi.org/10.1158/1078-0432.CCR-12-1557

[4] Pineda, E., Domenech, M., Hernández, A., Comas, S., & Balaña, C. (2023). Recurrent glioblastoma: Ongoing clinical challenges and future prospects. OncoTargets and Therapy, 16, 71-86. https://doi.org/10.2147/OTT.S366371

[5] Kawabata, S., Suzuki, M., Hirose, K., Tanaka, H., Kato, T., Goto, H., ..., & Miyatake, S. I. (2021). Accelerator—based BNCT for patients with recurrent glioblastoma: A multicenter phase II study. Neuro—Oncology Advances, 3(1), vdab067. https://doi.org/10.1093/noajnl/vdab067

[6] Weathers, S. P., & de Groot, J. (2015). VEGF manipulation in glioblastoma. Oncology, 29(10), 720-727.

[7] Taylor, O. G., Brzozowski, J. S., & Skelding, K. A. (2019). Glioblastoma multiforme: An overview of emerging therapeutic targets. Frontiers in Oncology, 9, 963. https://doi.org/10.3389/fonc.2019.00963

[8] Arya, K. R., Bharath Chand, R. P., Abhinand, C. S., Nair, A. S., Oommen, O. V., & Sudhakaran, P. R. (2021). Identification of hub genes and key pathways associated with anti—VEGF resistant glioblastoma using gene expression data analysis. Biomolecules, 11(3), 403. https://doi.org/10.3390/biom11030403

[9] Ramawat, B., Jangid, V., & Samagandi, K. (2022). Review article on the role of Medhya Rasayana: Enhancing the intellectual power. Journal of Ayurveda and Integrated Medical Sciences, 7(5), 69-74. https://jaims.in/jaims/article/view/1882

[10] Sunitha, P., Raju, R., Sajil, C. K., Abhinand, C. S., Nair, A. S., Oommen, O. V., ..., & Sudhakaran, P. R. (2019). Temporal VEGFA responsive genes in HUVECs: Gene signatures and potential ligands/receptors fine—tuning angiogenesis. Journal of Cell Communication and Signaling, 13, 561-571. https://doi.org/10.1007/s12079-019-00541-7

[11] Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 64, 4-17. https://doi.org/10.1016/j.addr.2012.09.019

[12] Butina, D., Segall, M. D., & Frankcombe, K. (2002). Predicting ADME properties in silico: Methods and models. Drug Discovery Today, 7(11), S83-S88. https://doi.org/10.1016/S1359-6446(02)02288-2

[13] Liu, Z. L., Chen, H. H., Zheng, L. L., Sun, L. P., & Shi, L. (2023). Angiogenic signaling pathways and anti—angiogenic therapy for cancer. Signal Transduction and Targeted Therapy, 8(1), 198. https://doi.org/10.1038/s41392-023-01460-1

[14] Qi,, S., Deng, S., Lian, Z., Lian, Z., & Yu, K. (2022). Novel drugs with high efficacy against tumor angiogenesis. International Journal of Molecular Sciences, 23(13), 6934. https://doi.org/10.3390/ijms23136934

[15] Acharya, V. J. T. (1941). Charaka Samhita (Sanskrit) of Agnivesha with Ayurveda Dipika commentary. India: Nirnaya Sagar Press.

[16] Rao, S. N., Head, M. S., Kulkarni, A., & LaLonde, J. M. (2007). Validation studies of the site—directed docking program LibDock. Journal of Chemical Information and Modeling, 47(6), 2159-2171. https://doi.org/10.1021/ci6004299

[17] Beschi, D. A., Appavoo, M. R., & Wilsy, J. I. (2021). GC—MS analysis, collected from Kavalkinaru area, Tirunelveli district, Tamil Nadu, India. European Journal of Molecular & Clinical Medicine, 8(11), 2021.

[18] Jayaraj, R. L., Beiram, R., Azimullah, S., Mf, N. M., Ojha, S. K., Adem, A., & Jalal, F. Y. (2020). Valeric acid protects dopaminergic neurons by suppressing oxidative stress, neuroinflammation and modulating autophagy pathways. International Journal of Molecular Sciences, 21(20), 7670. https://doi.org/10.3390/ijms21207670

[19] Han, R., Nusbaum, O., Chen, X., & Zhu, Y. (2020). Valeric acid suppresses liver cancer development by acting as a novel HDAC inhibitor. Molecular Therapy—Oncolytics, 19, 8-18. https://doi.org/10.1016/j.omto.2020.08.017

[20] Chen, H., Tang, X., Liu, T., Jing, L., & Wu, J. (2019). Zingiberene inhibits in vitro and in vivo human colon cancer cell growth via autophagy induction, suppression of PI3K/AKT/mTOR Pathway and caspase 2 deactivation. Journal of BUON, 24(4), 1470-1475.

[21] Ashokkumar, K., Murugan, M., Dhanya, M. K., Sathyan, T., Raj, S., & Mathews, N. (2020). Traditional uses, phytochemistry, and pharmacological properties of Zingiber officinale essential oil and extracts. In N. Mishra (Ed.), Ethnopharmacological investigation of Indian spices (pp. 62-84). IGI Global. https://doi.org/10.4018/978-1-7998-2524-1.ch005

[22] Wang, Z. F., Liu, J., Yang, Y. A., & Zhu, H. L. (2020). A review: The anti—inflammatory, anticancer and antibacterial properties of four kinds of licorice flavonoids isolated from licorice. Current Medicinal Chemistry, 27(12), 1997-2011. https://doi.org/10.2174/0929867325666181001104550

[23] Alibakhshi, A., Malekzadeh, R., Hosseini, S. A., & Yaghoobi, H. (2023). Investigation of the therapeutic role of native plant compounds against colorectal cancer based on system biology and virtual screening. Scientific Reports, 13(1), 11451. https://doi.org/10.1038/s41598-023-38134-5

[24] Fukuzawa, M., Yamaguchi, R., Hide, I., Chen, Z., Hirai, Y., Sugimoto, A., ..., & Nakata, Y. (2008). Possible involvement of long chain fatty acids in the spores of Ganoderma lucidum (Reishi Houshi) to its anti—tumor activity. Biological and Pharmaceutical Bulletin, 31(10), 1933-1937. https://doi.org/10.1248/bpb.31.1933

[25] El—Sawy, E., Abo—Salem, H., & Mandour, A. (2017). 1H—Indole—3—carboxaldehyde: Synthesis and reactions. Egyptian Journal of Chemistry, 60(5), 723-751. https://doi.org/10.21608/ejchem.2017.1097.1053

[26] Bouone, Y. O., Bouzina, A., Sayad, R., Djemel, A., Benaceur, F., Zoukel, A., ..., & Bouchareb, F. (2023). BiCl₃—catalyzed green synthesis of 4—hydroxy—2—quinolone analogues under microwave irradiation . RSC Advances, 13(40), 28030-28041. https://doi.org/10.1039/D3RA05289C

[27] Liu, Y., Xie, S., Wang, Y., Luo, K., Wang, Y., & Cai, Y. (2012). Liquiritigenin inhibits tumor growth and vascularization in a mouse model of HeLa cells. Molecules, 17(6), 7206-7216. https://doi.org/10.3390/molecules17067206

[28] Stamos, J., Sliwkowski, M. X., & Eigenbrot, C. (2002). Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4—anilinoquinazoline inhibitor. Journal of Biological Chemistry, 277(48), 46265-46272. https://doi.org/10.1074/jbc.M207135200

[29] Lucido, M. J., Orlando, B. J., Vecchio, A. J., & Malkowski, M. G. (2016). Crystal structure of aspirin—acetylated human cyclooxygenase—2: Insight into the formation of products with reversed stereochemistry. Biochemistry, 55(8), 1226-1238. https://doi.org/10.1021/acs.biochem.5b01378

[30] Llinas, P., Hélène Le Du, M., Gårdsvoll, H., Danø, K., Ploug, M., Gilquin, B., ..., & Ménez, A. (2005). Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. The EMBO Journal, 24(9), 1655-1663. https://doi.org/10.1038/sj.emboj.7600635